Cingulate Inc.
CINGW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.88K in total; no superinvestor holds it.
Other share classesCING
Q2 2026 vs. Q1 2026
How the institutions holding Cingulate Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 4 | 8 | +4 |
| Shares | 30.3K | 124.2K | +93.9K (+310.3%) |
| Value | $917 | $1.88K | +$961 (+104.8%) |
New holders (6)
Institutions that held Cingulate Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MAI Capital Management | 26,021 | $497 | 0.00% |
| Susquehanna International Group, LLP | 23,080 | $441 | 0.00% |
| Two Sigma Securities, LLC | 10,918 | $209 | 0.00% |
| Toronto Dominion Bank | 100 | $2 | 0.00% |
| HRT Financial LP | 13,224 | $0 | 0.00% |
| Virtu Financial LLC | 12,626 | $0 | 0.00% |
Sold out (2)
Institutions that held Cingulate Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Citadel Advisors LLC | 11,486 | $348 |
| UBS Group AG | 580 | $17 |